|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Absence of AKT1 mutations in glioblastoma.
|
19461960 |
2009 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, the differential expression of the immunomodulatory molecule YKL-40 may affect the treatment efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma.
|
29729901 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma.
|
30731398 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model.
|
28616662 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-562 negatively regulated c-MET/AKT pathway in the growth of glioblastoma cells.
|
30613151 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the AKT pathway in glioblastoma.
|
21827416 |
2011 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study also demonstrated that vitexin inhibited RAC‑alpha serine/threonine‑protein kinase (Akt)/mechanistic target of rapamycin kinase (mTOR) signaling in human glioblastoma cells.
|
29328424 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GSH depletion and consequent AKT inhibition contribute to the Nrf2 knockdown-induced decrease in proliferation in glioblastoma U251 cells.
|
28260004 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reproducible profiles emerged, in which multiple therapeutic targets significant to glioblastoma [matrix metalloproteinases, AKT1 (v-akt murine thymoma viral oncogene homolog 1), epidermal growth factor receptor, vascular endothelial growth factor] showed significant differences in regional expression that may affect treatment response.
|
17122647 |
2006 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To delineate the possible signaling pathways involved in the magnolol-induced increases of p27/Kip1 expression and apoptosis, we found that magnolol (100 μM) increased the levels of phosphorylated cSrc (p-cSrc), p-ERK, p-p38 MAP kinase (p-p38 MAPK), and p-AKT but not p-JNK in U373.
|
23448150 |
2013 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCR4 Signaling Induced Epithelial-Mesenchymal Transition by PI3K/AKT and ERK Pathways in Glioblastoma.
|
25326893 |
2015 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells.
|
30116397 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression.
|
27422127 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
|
31243804 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKT pathway genes define 5 prognostic subgroups in glioblastoma.
|
24984002 |
2014 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety.
|
31541850 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
|
30357833 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
|
28320338 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A.
|
22337773 |
2012 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, SDF-1-CXCR4 pathway induced the expression of AGR2 to control the progression of EMT likely via AKT pathway in the development of glioblastoma.
|
26608373 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKT/GSK3β Signaling in Glioblastoma.
|
27568206 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It inhibits signaling through the PI3/AKT axis and other cascades of biologic importance in glioblastoma, and has promising pre-clinical activity in vitro and in vivo.
|
31325145 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that patient-derived glioblastoma stem cells in the context of ERK and AKT activation are sensitive and highly regulated by neddylation inhibition.
|
31771104 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
|
30420967 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to promising results of preclinical studies investigating the PI3K/AKT pathway in grade IV brain tumors like glioblastoma and medulloblastoma, the components of this pathway have emerged as promising therapeutic targets to treat these malignant brain tumors.
|
21861842 |
2011 |